2.Infection in Children with Acute Myeloid Leukemia in the Intensive Chemotherapy Period.
Kai Lan CHEN ; Hao XIONG ; Jian Xin LI ; Fang TAO ; Bing WU ; Zhuo WANG ; Ying Ming NIE ; Hui LI
Journal of Experimental Hematology 2021;29(5):1649-1653
OBJECTIVE:
To investigate the clinical characteristics of infection in children with acute myeloid leukemia (AML) after high intensive chemotherapy, so as to provide reference for prevention and control of infection.
METHODS:
56 children diagnosed as acute myeloid leukemia in our hospital from January 2016 to August 2019 were enrolled and retrospectively analyzed, the infection rate, pathogens of disease and common location of infection during the induction and consolidation period were analyzed.
RESULTS:
The total infection rate of the patients was 93.4%-96.4%, the average of serious infection rate was 16.0%(11.3%-19.6%), and the infection related mortality was 10.7%. Fever of unknown cause was the main reason of infection, while blood flow infections were the most common in severe infection, which were mainly caused by Gramnegative bacteria. The rate of fungal infection was 35.7% during chemotherapy.
CONCLUSION
Children with AML shows a high incidence of infection in each stage of chemotherapy. The serious illness caused by blood flow infection and take antifungal drugs to reduce the occurrence of fungal infection in AML patients should be paid attention.
Antifungal Agents/therapeutic use*
;
Child
;
Fever/drug therapy*
;
Humans
;
Leukemia, Myeloid, Acute/drug therapy*
;
Mycoses/drug therapy*
;
Retrospective Studies
3.Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients with Advanced Gastric Cancer.
Sung Hwan SUH ; Hyuk Chan KWON ; Ji Hoon JO ; Young Rak CHO ; Bong Gun SEO ; Dong Mee LEE ; Sung Hyun KIM ; Jae Seok KIM ; Hyo Jin KIM
Cancer Research and Treatment 2005;37(5):279-283
PURPOSE: To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients. MATERIALS AND METHODS: Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion on the first day plus LV 20 mg/m2 over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m2 followed by a 22-hour continuous infusion of 600 mg/m2 on days 1~2. The treatment was repeated at 2 week intervals. RESULTS: The median age of the patients was 50 years (range: 31~74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the 30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5~32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6~4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9~9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic fever occurred during only 2 of the 178 cycles. The most common non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths. CONCLUSIONS: The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.
Diarrhea
;
Drug Therapy
;
Fever
;
Fluorouracil*
;
Humans
;
Leucovorin*
;
Neutropenia
;
Salvage Therapy*
;
Stomach Neoplasms*
;
Thrombocytopenia
4.Primary Renal Lymphoma in a Child.
Seong Min LEE ; In Cheol SON ; Joa Jun KIM ; Tack LEE ; Sang Min YOON ; Soon Gi KIM
Korean Journal of Urology 2001;42(11):1220-1223
Primary renal lymphoma is a controversial entity and extremely rare disease, possibly due to the fact that the kidney is one of the extranodal organs usually not containing lymphoid tissue. It is unclear if this conditions can be diagnosed preoperatively with imaging studies. In most cases the diagnosis is made after removal or biopsy of a kidney for suspected primary renal tumor or at autopsy. Treatment usually consists of surgery and chemotherapy with or without radiation therapy and the prognosis is poor. We report a case of primary renal lymphoma presenting with fever in a 13-month- old boy who was treated with surgical intervention and combination chemotherapy.
Autopsy
;
Biopsy
;
Child*
;
Diagnosis
;
Drug Therapy
;
Drug Therapy, Combination
;
Fever
;
Humans
;
Kidney
;
Lymphoid Tissue
;
Lymphoma*
;
Male
;
Prognosis
;
Rare Diseases
6.A case with systemic disseminated fungal disease and reactive histiocytosis.
Chinese Journal of Pediatrics 2004;42(5):397-397
Antifungal Agents
;
therapeutic use
;
Fever
;
Histiocytosis
;
drug therapy
;
etiology
;
Humans
;
Infant
;
Lung Diseases, Fungal
;
complications
;
diagnosis
;
drug therapy
;
Male
7.Randomized double-blind parallel controlled multicenter trial of Reyanning Mixture in treatment of acute tonsillitis.
Jian LYU ; Cui YANG ; Lian-Xin WANG ; Yan-Ming XIE ; Xue-Qing YU ; Li GU ; Feng GAO ; Jing-Xiao ZHANG ; Xiao-Kang YU
China Journal of Chinese Materia Medica 2020;45(14):3282-3291
This study is a randomized controlled trial of Reyanning Mixture in the treatment of acute tonsillitis. According to the ratio of 1∶1∶1, a total of 144 patients were randomly divided into Reyanning Mixture group(RYN), Reyanning Mixture+Amoxicillin Capsules group(RYN+Amoxil) and Amoxicillin Capsules group(Amoxil), with 48 cases in each group, in order to evaluate the efficacy and safety of RYN alone or combined with Amoxil in the treatment of acute tonsillitis, and provided high-quality evidences for treatment of infectious diseases with traditional Chinese medicine and reduced use of antibiotics. The dosage of RYN was 20 mL, 3 times a day, 100 mL/bottle, oral for 7 days, and Amoxil dosage was 0.5 g, 3 times a day, 0.5 g×12 tablets/plate, oral for 7 days. A total of 144 cases were included, 3 cases were excluded(1 case was mistakenly included, 2 cases did not take drugs after inclu-ded), and a total of 141 cases were included in the full analysis set(FAS). The results showed statistical differences in the recovery time of the disease, the disappearance rate of fever on the 3 rd day and the disappearance rate of tonsillar redness and swelling between RYN and Amoxil. There were statistical differences in the cure rate of disease, recovery time of disease, body temperature recovery time, fever disappearance rate on the 3 rd day, pharynx swelling and pain disappearance rate and tonsil swelling disappearance rate between the RYN+Amoxil and Amoxil, but with no significant difference in the above aspects compared with RYN. The DDD of antibiotic use in RYN+Amoxil was significantly lower than that in Amoxil(P<0.01). According to the findings, when RYN was used alone in the treatment of acute tonsillitis, it was superior to Amoxil in time of recovery, short-term improvement of fever and redness and swelling of tonsil. Compared with RYN+Amoxil, there was no difference in cure rate of disease, recovery time of disease, body temperature recovery time, short-term improvement of fever, swelling of pharynx and swelling of tonsil, with a better efficacy than Amoxil. The clinical effect of RYN was similar to that of combined Amoxil in the treatment of acute tonsillitis, and RYN was superior to Amoxil in the time of recovery, short-term improvement of fever and redness and swelling of tonsil, with no adverse event or adverse reaction. RYN+Amoxil can significantly reduce the DDD value of antibiotics in the treatment of acute tonsillitis, with significant clinical advantages over Amoxil.
Anti-Bacterial Agents
;
therapeutic use
;
Double-Blind Method
;
Drugs, Chinese Herbal
;
Fever
;
drug therapy
;
Humans
;
Tonsillitis
;
drug therapy
8.Exploration of Chaige Jieji Decoction formula syndromes based on severe cases of critical care and its application for acute exogenous fever and nosocomial infection.
China Journal of Chinese Materia Medica 2019;44(18):3876-3882
Chaige Jieji Decoction recorded in Six Books of Exogenous Febrile Disease could be used to treat exterior syndrome due to wind-cold and heat caused by stagnation. The indications of Chaige Jieji Decoction include acute exogenous febrile diseases,such as influenza,upper respiratory tract infection,nosocomial infection; symptoms and signs,such as headache,eye pain,orbital pain,dizziness; fever,cold and hot exchanges; dry mouth,thirst,cold drinks,bitter mouth,dry throat; dry nose,stuffy nose,runny nose; poor appetite,silent appetite; strong neck,stiff back; insomnia,difficulty in sleeping; cough and sputum; abdominal pain,limb twitching;slightly torrent pulse. Disease involving all three Yang channels is very common in acute exogenous febrile diseases; the pathogenesis of exogenous diseases is quite different between cases in South China and North China. Most of the exogenous diseases in North China involves all three Yang channels. Disease involving all three Yang channels is the core of the pathogenesis of Chaige Jieji Decoction syndrome,in which headache is the key indications. Chaige Jieji Decoction can not only treat exogenous diseases,but also treat nosocomial infections in critically ill patients during hospitalization. Although Chaige Jieji Decoction,Xiaochaihu-Maxing Shigan Decoction,and Xiaochaihu-Daqinglong Decoction could be used to treat disease involving all three Yang channels,there are differences in indicators among them.
China
;
Critical Care
;
Cross Infection/drug therapy*
;
Drugs, Chinese Herbal/pharmacology*
;
Fever/drug therapy*
;
Humans
;
Medicine, Chinese Traditional
;
Syndrome
9.A Case of Cytophagic Histiocytic Panniculitis Involving the Extrapleural Fat.
Jong Keun SEO ; Joon Hee CHOI ; Sang Min LEE ; Sook Kyung LEE
Korean Journal of Dermatology 2007;45(2):180-184
Cytophagic histiocytic panniculitis gap (CHP) was described in 1980 as a chronic histiocytic disease of the subcutaneous tissue and associated with systemic manifestations such as fever, serositis, and hepatosplenomegaly. The current concept of CHP is that it represents a spectrum of lymphoproliferative disorders that induce secondary histiocytic cytophagocytosis. The pathogenesis of hemophagocytosis in CHP is unknown but may be related to histiocyte reaction to an abnormal cytokine milieu brought about by disordered T-cell function. In most cases the disease follows a fulminant course, but in some patients the disease seems limited to the skin and subcutaneous tissue and follows a more benign, chronic course. We report a case of cytophagic histiocytic panniculitis which had a long chronic course over 16 years, but recently became aggravated with the involvement of the extrapleural fat tissue and was treated with combination chemotherapy.
Cytophagocytosis
;
Drug Therapy, Combination
;
Fever
;
Histiocytes
;
Humans
;
Lymphoproliferative Disorders
;
Panniculitis*
;
Serositis
;
Skin
;
Subcutaneous Tissue
;
T-Lymphocytes
10.A Phase II Study of Leucovorin, 5-FU and Docetaxel Combination Chemotherapy in Patients with Inoperable or Postoperative Relapsed Gastric Cancer.
Kwang Sun LEE ; Ha Yeon LEE ; Eun Kyung PARK ; Joung Soon JANG ; Sang Jae LEE
Cancer Research and Treatment 2008;40(1):11-15
PURPOSE: To estimate the effect and toxicity of bimonthly low-dose leucovorin (LV) and fluorouracil (5-FU) bolus plus continuous infusion(LV5FU2) with docetaxel combination chemotheraphy in patients with inoperable or postoperative relapsed gastric cancer. MATERIALS AND METHODS: Total 27 patients are enrolled in this study. LV 20 mg/m2 (bolus), 5FU 400 mg/m2 (bolus), 5-FU 600 mg/m2 (24-hour continuous infusion) on day 1, 2, 15, and 16, docetaxel 60 mg/m2 (1-hour infusion) on day 15 every 4 weeks. RESULTS: Total of 141 cycles were administered and response rate were 36.8% with 2 complete response (10.5%) and 5 partial response (26.3%) in 19 evaluable patients. The median response duration is 8.1 months (95% CI, 4.0~12.1). The median progression-free survival time is 6.7 months (95% CI, 5.0~8.5) and the median overall survival time is 11.9 months (95% CI, 4.8~19.1). The grade 3-4 toxcity of neutropenia (24.8%) and anemia (11.3%), neutropenic fever (2.8%) is observed. The grade 1 toxcity of injection site reaction is observed all patients and the grade 1-2 toxcity of alopecia is observed 60%. CONCLUSIONS: LV5FU2 with docetaxel combination chemotheraphy is effective and tolerable in patients with inoperable or postoperative relapsed gastric cancer.
Alopecia
;
Anemia
;
Disease-Free Survival
;
Drug Therapy, Combination
;
Fever
;
Fluorouracil
;
Humans
;
Leucovorin
;
Neutropenia
;
Stomach Neoplasms
;
Taxoids